Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 5/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410216 | 0.76 | FFAR4 (0.37) | FFAR4DPP4TACR1NOTUMHIF1A | |
| SCHEMBL14300689 | 0.73 | FFAR4 (0.38) | FFAR4NOTUMPOLBHIF1AHSD17B10 | |
| SCHEMBL14300691 | 0.73 | FFAR4 (0.38) | FFAR4NOTUMPOLBHIF1AHSD17B10 | |
| SCHEMBL1410258 | 0.72 | FFAR4 (0.44) | FFAR4DPP4TACR1NOTUM | |
| SCHEMBL1410217 | 0.69 | FFAR4 (0.37) | FFAR4DPP4TACR1NOTUMHIF1A | |
| SCHEMBL1410142 | 0.68 | ALDH1A1 (0.37) | FFAR4DPP4POLBMAPTALDH1A1 | |
| SCHEMBL14300690 | 0.66 | FFAR4 (0.38) | FFAR4NOTUMPOLBHIF1AHSD17B10 | |
| SCHEMBL14300692 | 0.66 | FFAR4 (0.38) | FFAR4NOTUMPOLBHIF1AHSD17B10 | |
| SCHEMBL1410260 | 0.65 | FFAR4 (0.44) | FFAR4DPP4TACR1NOTUM | |
| SCHEMBL1410213 | 0.63 | ALDH1A1 (0.36) | FFAR4TACR1ALDH1A1HSP90AA1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | FFAR4 4589/4885DPP4 1356/4885TACR1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.